Joao P De Aquino1, Christopher Fairgrieve, Sukhpreet Klaire, Gabriela Garcia-Vassallo. 1. Department of Psychiatry, Yale University School of Medicine, New Haven, CT (JPD, GG-V); U.S. Department of Veterans Affairs, VA Connecticut Healthcare System, West Haven, CT (JPD, GG-V); Center for Addiction and Mental Health, Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada (CF); British Columbia Centre on Substance Use and Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada (SK).
Abstract
OBJECTIVES: Alternative transition protocols from methadone to buprenorphine in the treatment of opioid use disorder (OUD) are needed to reduce the risk of precipitated withdrawal and opioid use during induction. METHODS: Case report (n = 1). RESULTS: One patient with OUD underwent a rapid microinduction outpatient protocol that did not cause precipitated withdrawal or require preceding taper before cessation of methadone. The induction was carried out safely in the outpatient setting. CONCLUSIONS: This report provides a patient-centered approach demonstrating feasibility and cost-effectiveness of rapid transition to buprenorphine in the US outpatient psychiatry setting. Barriers to adherence to opioid agonist therapy may be reduced using this protocol.
OBJECTIVES: Alternative transition protocols from methadone to buprenorphine in the treatment of opioid use disorder (OUD) are needed to reduce the risk of precipitated withdrawal and opioid use during induction. METHODS: Case report (n = 1). RESULTS: One patient with OUD underwent a rapid microinduction outpatient protocol that did not cause precipitated withdrawal or require preceding taper before cessation of methadone. The induction was carried out safely in the outpatient setting. CONCLUSIONS: This report provides a patient-centered approach demonstrating feasibility and cost-effectiveness of rapid transition to buprenorphine in the US outpatient psychiatry setting. Barriers to adherence to opioid agonist therapy may be reduced using this protocol.
Authors: Fabio Lugoboni; Antonio Mirijello; Lorenzo Zamboni; Marco Faccini; Rebecca Casari; Anthony Cossari; Antonio Gasbarrini; Giovanni Addolorato Journal: Expert Opin Pharmacother Date: 2016-09-21 Impact factor: 3.889
Authors: Catherine Anne Fullerton; Meelee Kim; Cindy Parks Thomas; D Russell Lyman; Leslie B Montejano; Richard H Dougherty; Allen S Daniels; Sushmita Shoma Ghose; Miriam E Delphin-Rittmon Journal: Psychiatr Serv Date: 2014-02-01 Impact factor: 3.084